Expanding Horizons in Liquid Nasal Drug Development

Liquid nasal drug delivery has evolved from simple local therapies into a highly versatile platform supporting rapid systemic delivery, emergency rescue medications, and emerging CNS-targeted treatments. As these applications expand, successful development increasingly depends on early, integrated alignment of formulation science, device selection, analytical control, and manufacturing strategy. In this article, Catalent experts Dr. Alan Watts and David Wilcox examine the current and emerging nasal delivery landscape and outline critical chemistry, manufacturing, and controls (CMC) considerations across development, scale-up, and commercial production. Drawing on real-world experience, the piece highlights practical strategies to reduce technical risk, support regulatory readiness, and enable robust, scalable liquid nasal drug products.